AI System Identifies Rare Heart Disease Gene, Enabling Earlier Intervention

A rare heart condition that silently destroys muscle tissue from the inside now has a new early warning system. Researchers at the Mayo Clinic have developed an artificial intelligence tool capable of identifying mutations in the PKP2 gene, which is the primary genetic driver of arrhythmogenic right ventricular cardiomyopathy, or ARVC. The significance of this breakthrough lies in timing: ARVC progresses without obvious symptoms in its early stages, and by the time most patients receive a diagnosis, their hearts have already sustained considerable damage.

ARVC is an inherited disorder in which the heart muscle gradually weakens and is replaced by fibrous, fatty scar tissue. The condition belongs to a family of genetic mutations—PKP2, DSG2, DSP, DSC2, and JUP genes are all implicated—but PKP2 accounts for the majority of cases. As the disease advances, the heart loses its ability to pump effectively, and the electrical system that maintains normal rhythm begins to malfunction. The Cleveland Clinic notes that ARVC carries a substantial risk of triggering abnormal heart rhythms, which underscores why early detection and intervention are critical.

The symptoms of ARVC, when they do appear, are often mistaken for other conditions or attributed to general fatigue. Patients report fainting episodes, shortness of breath, swelling in the feet, legs, ankles, and abdomen, chest palpitations or fluttering sensations, persistent fatigue, and chest pain. By the time these warning signs become noticeable enough to prompt medical evaluation, the underlying tissue damage may already be advanced. This lag between disease onset and diagnosis has long been one of the most frustrating aspects of ARVC management.

The Mayo Clinic's AI system changes this calculus. By analyzing genetic data and identifying PKP2 mutations before symptoms emerge, the tool makes it possible to intervene earlier in the disease process. This matters enormously for patients who carry the mutation but have not yet experienced the cascade of heart damage. Early identification allows physicians to begin monitoring more closely, adjust lifestyle factors, and consider preventive treatments that might slow or halt progression.

The development of this AI-based genetic screening represents a shift in how rare inherited heart diseases are managed. Rather than waiting for a patient to faint or experience chest pain—events that may already indicate substantial cardiac compromise—clinicians can now identify at-risk individuals through genetic testing and AI analysis. For families with known histories of ARVC, this capability offers the possibility of screening relatives before they develop symptoms. For the broader population, it opens a pathway to catching the condition in its earliest, most treatable phase.